DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM Jun 26, 2018
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors Jun 25, 2018
DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM Apr 17, 2018
DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research Apr 16, 2018
DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma Dec 26, 2017
